Cytokinetics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuits Against Cytokinetics, Incorporated - CYTK

Core Points - Cytokinetics, Incorporated is facing a securities class action lawsuit for failing to disclose material information during the class period from December 27, 2023, to May 6, 2025 [1][3] - Investors have until November 17, 2025, to file lead plaintiff applications related to this lawsuit [1] - The lawsuit is currently pending in the United States District Court for the Northern District of California [1] Company Actions - On March 10, 2025, Cytokinetics announced that the FDA would not hold an advisory committee meeting to review its New Drug Application (NDA) for the aficamten product [4] - On May 6, 2025, the company revealed it had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy [4] - Following these announcements, Cytokinetics' share price fell to $33.04 per share on May 7, 2025 [5] Legal Information - The case is identified as Seidman v. Cytokinetics, Incorporated, et al., No. 25-cv-07923 [5] - Kahn Swick & Foti, LLC is available to discuss legal options for affected investors [2]